Abstract:Purpose: Neurofibromatosis type 1(NF1) and type 2(NF2) are both autosomal dominantly inherited disorders and originate from schwann cells. This study was done to investigate the genetic and proteomic profiles of the tumours.Methods: Mutational analyses of neurofibromatosis type 1 and type 2 genes (NF1 and NF2) in 15 NF1 and NF2 patients were carried out using Sanger sequencing. TMT-labeled spectrometry analysis was used to identify the proteome of neurofibromatosis type 1 and type 2 relative to nerve controls. Loss of heterozygosity were analysed for the candidate gene EPB41L3. Protein expression of tumour tissues/cultures was assessed by Western blots and/or immunofluorescence.Finds: DNA sequencing showed frequent mutations within NF1 or NF2 in the neurofibromatosis type 1 and type 2, respectively. 159 proteins were significantly differentially expressed in NF1 compared with normal nerves, and 180 proteins were significantly differentially expressed in NF2 compared with normal nerves. Among these, 11 were found commonly up-regulated and 30 down-regulated in both tumors. Among the commonly significantly down-regulated proteins in both tumors we consistently find EPB41L3.The EPB41L3 tumour suppressor showed the most significantly decreased expression, and existed predominantly at the cytoplasm of HEI193 and NF1 cell cultures. Western blot analysis identified the down-regulation in the NF1 and NF2 association with neurofibromin and merlin, respectively. LOH of EPB41L3 was more common among neurofibromatosis type 1(seen in 3 of 5 tumors, 60%) and least common among neurofibromatosis type 2 (2 of 10, 20%).Interpretation: Our data first get an insight into the common molecular mechanisms of neurofibroma, that indicates the potential role of EPB41L3 as a therapeutic target for this tumor syndrome.Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 82171366 to Wei Chen; No. 82070541, 81600625, both to ML; 81771332, 81571184, both to CZ; 82172820 to JZ).and Grant No. 19ZR1447400 to Wei Chen. Jiangxi province outstanding poject (Grant No.20202ACBL216005 to Wei Chen); the Health Industry Clinical Research Project of Shanghai Municipal Health Commission (No. 20204125, to ML; No. 201840110, to SX); the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (No. PWR12018-07, to CZ);the Key Discipline Construction Project of Pudong Health Bureau of Shanghai (No. PWZxk2017-23, to CZ); the Top-level Clinical Discipline Project of Shanghai Pudong (No. PWYgf2018-05, to CZ) .Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: Informed written consent was obtained from all patients donating tissue. This study was approved by the Institutional Review Board of the ethics committee of The shanghai east Hospital affiliated to School of Medicine, Shanghai Tong Ji University.

Synergistic Effect of Nutlin-3 Combined with MG-132 on Schwannoma Cells Through Restoration of Merlin and P53 Tumour Suppressors

Proteomic Screening Identifies PML/p53 Axis As a Potential Treatment Target of Facial Nerve Schwannomas.

Synergistic Effect of Erastin Combined with Nutlin-3 on Vestibular Schwannoma Cells as p53 Modulates Erastin-Induced Ferroptosis Response

P14ARF Deficiency and Its Correlation with Overexpression of P53/mdm2 in Sporadic Vestibular Schwannomas.

Merlin Cooperates with Neurofibromin and Spred1 to Suppress the Ras-Erk Pathway.

Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and Its Prognostic Impact on Tumour Growth Patterns

Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated Schwann cell proliferation in human.

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

The Phosphorylation Status of Merlin in Sporadic Vestibular Schwannomas.

Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Screening in NF2-associated Schwannoma.

The NF2 Tumor Suppressor Merlin Interacts with Ras and RasGAP, Which May Modulate Ras Signaling

The CREB-binding Protein Inhibitor ICG-001: a Promising Therapeutic Strategy in Sporadic Meningioma with NF2 Mutations.

Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

Csig-19. Identification And Targeting Of Tumor Driver Schwann(Nf2Loss) Cells In Sporadic And Nf2-Related Vestibular Schwannomas

Combined Mtor/mek Inhibition Prevents Proliferation and Induces Apoptosis in NF2-mutant Tumors

MerlinS13 phosphorylation regulates meningioma Wnt signaling and magnetic resonance imaging features

Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

P53 Performs an Essential Role in Mediating the Oncogenic Stimulus Triggered by Loss of Expression of Neurofibromatosis Type 2 During in Vitro Tumor Progression.